Maverick Capital’s Moderna MRNA Stock Holding History

Maverick Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,277	Closed	-$238K	–	814
2020 Q4	$238K	Buy	+2,277	New	+$230K	﹤0.01%	501

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Maverick Capital's MRNA Position: Q1 2021 in Review

Maverick Capital sold out of Moderna (MRNA) in Q1 2021, closing a stake of 2,277 shares — an estimated $238K sold.

Maverick Capital first reported a position in MRNA in Q4 2020 and held it in 1 quarter. The position peaked at $238K in Q4 2020. 776 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

Maverick Capital reported no remaining Moderna position as of Q1 2021 after selling out during the quarter.
Maverick Capital sold 2,277 Moderna shares in Q1 2021, an estimated $238K.
Maverick Capital first reported a position in Moderna in Q4 2020 and held it in 1 quarter.
Maverick Capital's Moderna position peaked at $238K in Q4 2020.
776 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on Maverick Capital's 13F filing for Q1 2021, filed 17 May 2021.